General
Preferred name
ABIRATERONE ACETATE
Synonyms
Zytiga ()
CB7630 ()
Abiraterone Acetate (CB7630) ()
CB7630, CB-7630 ()
Abiraterone Acetate-d4 ()
Abiraterone mylan ()
Abiraterone accord ()
NSC-748121 ()
Abiraterone krka ()
NSC-749227 ()
Yonsa ()
CB-7630 ()
Abiraterone acetate component of akeega ()
P&D ID
PD012199
CAS
154229-18-2
2122245-63-8
Tags
available
prodrug
drug
Approved by
FDA
EMA
First approval
2011
Drug indication
prostate carcinoma
Prostate cancer
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Abiraterone acetate is an ester prodrug of the steroidal drug abiraterone, which acts as an androgen synthesis inhibitor by inhibiting steroid 17alpha-monooxygenase. (GtoPdb)
DESCRIPTION Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of CYP17A1 with antiandrogen activity. Abiraterone acetate is a proagent form of Abiraterone (CB7598).
PRICE 39
DESCRIPTION AAK1 and BMP2K inhibitor; activates Wnt signaling (Tocris Bioactive Compound Library)
DESCRIPTION Abiraterone acetate is an oral, potent, selective, and irreversible inhibitor of steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1) with antiandrogen activity. Abiraterone acetate is a prodrug form of abiraterone. (Enamine Bioactive Compounds)
DESCRIPTION Abiraterone Acetate (CB7630) is an androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER. (TargetMol Bioactive Compound Library)
Cell lines
4
Organisms
0
Compound Sets
20
AdooQ Bioactive Compound Library
A11058
Axon Medchem Screening Library
1874
Cayman Chemical Bioactives
15148
22096
ChEMBL Approved Drugs
CHEMBL271227
ChEMBL Drugs
CHEMBL271227
Drug Repurposing Hub
DrugCentral
4176
DrugCentral Approved Drugs
4176
DrugMAP
DMANBZI
DrugMAP Approved Drugs
DMANBZI
Enamine Bioactive Compounds
EBC-23629
EU-OPENSCREEN Bioactive Compound Library
EOS101365
Guide to Pharmacology
9288
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL271227
MedChem Express Bioactive Compound Library
HY-75054
Natural product-based probes and drugs
Novartis Chemogenetic Library (NIBR MoA Box)
Selleckchem Bioactive Compound Library
Abiraterone-Acetate-CB7630
TargetMol Bioactive Compound Library
T6215
Tocris Bioactive Compound Library
6520
External IDs
42
Properties
(calculated by RDKit )
Molecular Weight
391.25
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
0
Rotatable Bonds
2
Ring Count
5
Aromatic Ring Count
1
cLogP
5.97
TPSA
39.19
Fraction CSP3
0.62
Chiral centers
6.0
Largest ring
6.0
QED
0.46
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
CYP17
Cytochrome P450
CYP17A1
CYP17A1 inhibitor
Androgen Receptor,P450 (e.g. CYP17)
MOA
P450 inhibitor
Inhibitor
Androgen Biosynthesis Inhibitors
Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors
androgen biosynthesis inhibitor
Member status
member
Indication
prostate cancer
Biosynthetic Origin
Terpenoid (Steroid)
Therapeutic Indication
Anticancer
Therapeutic Class
Anticancer Agents
Pathway
Metabolic Enzyme/Protease
Metabolism
Source data